Thursday, June 18, 2026
RESI San Diego pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High BIOTECH 4 DAYS AWAY

RESI San Diego — 2026 — JULEP Venue San Diego, San Diego, USA

RESI Boston 2026, a key component of Biotech Week Boston, will take place on September 22-23 at the Westin Copley Place, followed by three days of virtual partnering on September 25,28-29. This hybrid format combines the benefits of in-person networking with the flexibility of on

JULEP Venue San Diego, San Diego, USA June 22 – June 23, 2026
300+ Attendees
6 Presentations
5 Companies
1 Drugs
All Events

Presentation data updated Jun 5, 2026, 11:28 AM UTC

Nova Event Impact Score
48 /100
  • Media coverage 10/20
  • Speaker quality 14/20
  • Pipeline relevance 1/20
  • Historical influence 13/20
  • Company participation 10/20

Key Takeaways

Key Themes

biotechRESIPipeline announcementsPartnership deals

Key Companies

Immunic, Inc.Fractyl HealthCabaletta BioExact Sciences (sponsor)Sutro Biopharma

Key Drugs

rese-cel

Key Markets

US Americas

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Investors & analysts

Key Data to Watch

Presentations ranked by investor impact score

ORAL Jun 22

Top-line Data Readout of the Twin Phase 3 ENSURE Trials

Immunic, Inc.$IMUX Phase Iii Multiple Sclerosis
INVESTOR IMPACT: ★★★★☆ 4/5
ORAL Jun 22

1-Year Data from the REVEAL-1 Cohort of Revita

Fractyl Health$GUTS Phase Ii Type 2 Diabetes / Obesity
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL Jun 23

1-Year Randomized Data from the REMAIN-1 Midpoint Cohort of Revita

Fractyl Health$GUTS Phase Ii Type 2 Diabetes / Obesity
INVESTOR IMPACT: ★★☆☆☆ 2/5
POSTER Jun 22

New Rese-cel Data in Dermatomyositis: 83% of Patients Would Have Met Registrational Primary Endpoint

Cabaletta Bio$CABA rese-cel Phase I Dermatomyositis
INVESTOR IMPACT: ★☆☆☆☆ 1/5
ORAL Jun 22

Initial Clinical Data from Sutro Biopharma Pipeline

Sutro Biopharma$STRO Phase I Cancer
INVESTOR IMPACT: ★☆☆☆☆ 1/5
POSTER Jun 23

Randomized EXALT-2 Trial: Clinical Utility and Health Outcomes

INVESTOR IMPACT: ★☆☆☆☆ 1/5